RegenXBio, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Mani Foroohar from Leerink Partners maintained a Buy rating on the stock and has a $20.00 price target.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Mani Foroohar has given his Buy rating due to a combination of factors including the potential for RegenXBio to capitalize on opportunities in the DMD market. The setbacks faced by a competitor have opened avenues for RegenXBio to differentiate itself, particularly in terms of safety, which aligns with the current FDA leadership’s focus. The company’s RGX-202 treatment for DMD is progressing well, with topline data expected in early 2026 and a BLA submission anticipated mid-year, supported by a strong safety profile and patient advocacy.
Additionally, Foroohar sees a high probability of approval for RGX-121 in MPS II by early 2026, alongside other promising developments such as the launch of Itvisma for SMA patients and advancements in wet AMD treatments. These factors, combined with strategic partnerships and potential revenue from new treatments, contribute to a positive outlook for RegenXBio, leading to an increased price target and a Buy rating.